NCT02008344CompletedPhase 3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Favipiravir in Adult Subjects With Uncomplicated Influenza
MDVI, LLC0 sites1,161 target enrollmentStarted: December 2013Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Enrollment
- 1,161
- Primary Endpoint
- Time to alleviation of all primary influenza symptoms and fever
Study Overview
Brief Summary
The purpose of this study is to determine if favipiravir is effective in reducing the time to resolution of influenza symptoms.
Detailed Description
The purpose of this study is to determine if a 5-day regimen of favipiravir reduces the time to alleviation of influenza symptoms, resolution of fever, and viral shedding, in subjects with uncomplicated influenza compared to no treatment (e.g. placebo).
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •At time of enrollment has 2 or more of the following symptoms (moderate to severe in intensity) that began 48 hours or less prior to the anticipated start of dosing with study medication: cough, sore throat, headache, nasal congestion, body aches and pains, fatigue
- •Has a fever at the first visit or in the 6 hours prior if antipyretics were taken, defined as: ≥ 38.0°C (≥ 100.4°F) if < 65 years old; or ≥ 37.8°C (≥ 100.0°F) if ≥ 65 years old
- •Tests positive for influenza A or B during the 48 hours between onset of symptoms and anticipated dosing with study medication as confirmed by RAT or PCR testing (study or non-study procedure); or per Investigator and Medical Monitor discretion in the event there is a known influenza outbreak circulating in the community or the subject has been in close contact with a person who was recently confirmed to have laboratory-confirmed influenza
- •Willing to adhere to strict contraceptive measures throughout study and for 3 months following last dose of study medication
Exclusion Criteria
- •Female subjects who are pregnant, currently breast-feeding, or have a positive pregnancy test at Screening
- •Has taken an anti-influenza drug, or received any live attenuated influenza vaccine within 4 weeks prior to signing the informed consent
- •Has underlying chronic respiratory disease; includes bronchial asthma if currently experience asthma symptoms, requires current asthma treatment, or has had an asthma attack in the past year
- •Is suspected of having bacterial respiratory infection (i.e., expectoration of purulent or mucopurulent sputum and/or infiltrate in lung observed on chest x ray, or is on antibiotics for pulmonary disease) at start of study
- •Has a history of gout or is under treatment for: gout or hyperuricemia; hereditary xanthinuria; hypouricemia or xanthine calculi of the urinary tract
- •Has a history of hypersensitivity to an anti-viral nucleoside-analog drug targeting a viral RNA polymerase
- •Current use of adrenocorticosteroids (except topical preparation) or immunosuppressive drugs
- •Has an allergy or contraindication to use of acetaminophen (paracetamol)
- •Has a serious chronic disease, history of alcohol or drug abuse within preceding 2 years, psychiatric illness not well controlled (not on stable regimen > 1 year), or is deemed by the Investigator to be ineligible for any reason
- •Previously participated in a clinical trial of favipiravir (T-705)
- •Has renal insufficiency requiring hemodialysis or continuous ambulatory peritoneal dialysis (CAPD)
Arms & Interventions
favipiravir
Active Comparator
Day 1: 1800 mg (1st loading dose), 1800 mg (2nd loading dose) Days 2-5: 800 mg BID (3rd to 10th dose)
Intervention: favipiravir (Drug)
placebo
Placebo Comparator
Day 1: 1800 mg (1st loading dose), 1800 mg (2nd loading dose) Days 2-5: 800 mg BID (3rd to 10th dose)
Intervention: placebo (Drug)
Outcomes
Primary Outcomes
Time to alleviation of all primary influenza symptoms and fever
Time Frame: 21 days
Time from the start of study treatment until alleviation of all primary influenza symptoms (i.e. cough, sore throat, headache, nasal congestion, body aches and pains, fatigue) and to resolution of fever
Secondary Outcomes
- Time to alleviation of each of the primary influenza symptoms and fever(21 days)
- To characterize the PK of favipiravir when used under clinical conditions(21 days)
Investigators
Similar Trials
Completed
Phase 3
Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults - T705US316InfluenzaNCT02026349MDVI, LLC860
Terminated
Phase 3
A Study of Rilematovir in Infants and Children and Subsequently in Neonates Hospitalized With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus (RSV)Respiratory Tract InfectionsNCT04583280Janssen Research & Development, LLC28
Completed
Phase 3
Vaniprevir Administered With Pegylated-interferon and Ribavirin in Japanese Treatment-Naïve Chronic Hepatitis C Participants (MK-7009-043)Hepatitis C, ChronicNCT01370642Merck Sharp & Dohme LLC294
Completed
Phase 2
Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19Sars-CoV2COVID-19NCT04346628Stanford University149
Completed
Phase 3
Efficacy and Safety of Favipiravir in Management of COVID-19Coronavirus Disease (COVID-19)NCT04349241Ain Shams University100